BACKGROUND: Privileged structures are potentially able to bind to a diverse range of biologically important proteins with high affinities, thus benefiting the discovery of novel bioactive compounds. 1,2-Benxisoxazole derivatives can be such important types of "privileged structures" possessing a rich diversity of biological properties especially in the area of CNS disorders. METHODS: This review seeks to explore the most significant examples of 1,2-benzisoxazoles as privileged structures in terms of polypharmacology at the molecular level, specifically focusing on four 1,2-benzisoxazoles (zonisamide, risperidone, paliperidone, and iloperidone) which have been in clinical use and established as effective therapeutics. Furthermore, an updated and detailed account of the pharmacological properties of 1,2-benzisoxazole derivatives as therapeutics for CNS disorders is described. And finally, outlooks on current issues and future directions in this field are also provided. RESULTS: 1,2-Benzisoxazole was successfully employed in the discovery and development of zonisamide for the treatment of epilepsy and Parkinson's disease. 1,2- Benzisoxazole is also a significantly important structure for the development of atypical antipsychotics. CONCLUSION: It is very reasonable to say that 1,2-benzisoxazole is a good example of a privileged structure because it forms the centerpiece of small molecule chemical entities with a wide range of pharmacological properties, especially in the area of CNS disorders.
BACKGROUND: Privileged structures are potentially able to bind to a diverse range of biologically important proteins with high affinities, thus benefiting the discovery of novel bioactive compounds. 1,2-Benxisoxazole derivatives can be such important types of "privileged structures" possessing a rich diversity of biological properties especially in the area of CNS disorders. METHODS: This review seeks to explore the most significant examples of 1,2-benzisoxazoles as privileged structures in terms of polypharmacology at the molecular level, specifically focusing on four 1,2-benzisoxazoles (zonisamide, risperidone, paliperidone, and iloperidone) which have been in clinical use and established as effective therapeutics. Furthermore, an updated and detailed account of the pharmacological properties of 1,2-benzisoxazole derivatives as therapeutics for CNS disorders is described. And finally, outlooks on current issues and future directions in this field are also provided. RESULTS:1,2-Benzisoxazole was successfully employed in the discovery and development of zonisamide for the treatment of epilepsy and Parkinson's disease. 1,2- Benzisoxazole is also a significantly important structure for the development of atypical antipsychotics. CONCLUSION: It is very reasonable to say that 1,2-benzisoxazole is a good example of a privileged structure because it forms the centerpiece of small molecule chemical entities with a wide range of pharmacological properties, especially in the area of CNS disorders.
Authors: João L Serrano; Pedro F Soeiro; Melani A Reis; Renato E F Boto; Samuel Silvestre; Paulo Almeida Journal: Mol Divers Date: 2019-03-14 Impact factor: 2.943
Authors: Robert W Deering; Kristen E Whalen; Ivan Alvarez; Kathryn Daffinee; Maya Beganovic; Kerry L LaPlante; Shreya Kishore; Sijing Zhao; Brent Cezairliyan; Shen Yu; Margaret Rosario; Tracy J Mincer; David C Rowley Journal: J Antibiot (Tokyo) Date: 2021-02-12 Impact factor: 2.649